Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 29 04 2024
accepted: 18 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

Understanding the level of exposure to Lassa virus (LASV) in at-risk communities allows for the administration of effective preventive interventions to mitigate epidemics of Lassa fever. We assessed the seroprevalence of LASV antibodies in rural and semiurban communities of two cosmopolitan cities in Nigeria with poorly understood Lassa epidemiology. A cross-sectional study was conducted in ten communities located in the Abuja Municipal Area Council (AMAC), Abuja, and Ikorodu Local Government Area (LGA), Lagos, from February 2nd to July 5th, 2022. Serum samples collected from participants were analyzed for IgG and IgM antibodies using a ReLASV A total of 628 participants with serum samples were included in the study. Most participants were female (434, 69%), married (459, 73%), and had a median age of 38 years (interquartile range 28-50). The overall seroprevalence was 27% (171/628), with a prevalence of 33% (126/376) in Abuja and 18% (45/252) in Lagos. Based on site-specific grouped LASSO selection, enrollment in the dry season (vs. wet; aPR, 95% CI: 1.73, 1.33-2.24), reported inconsistent washing of fruits and vegetables (aPR, 95% CI: 1.45, 1.10-1.92), and a positive malaria rapid test (aPR, 95% CI: 1.48, 1.09-2.00) were independently associated with LASV seropositivity in Abuja, whereas, only a self-reported history of rhinorrhea (PR, 95% CI: 2.21, 1.31-3.72) was independently associated with Lassa seropositivity in Lagos. The LASV seroprevalence was comparable to that in other areas in Nigeria. Our findings corroborate those from other studies on the importance of limiting human exposure to rodents and focusing on behavioral factors such as poor hygiene practices to reduce exposure to LASV.

Sections du résumé

BACKGROUND BACKGROUND
Understanding the level of exposure to Lassa virus (LASV) in at-risk communities allows for the administration of effective preventive interventions to mitigate epidemics of Lassa fever. We assessed the seroprevalence of LASV antibodies in rural and semiurban communities of two cosmopolitan cities in Nigeria with poorly understood Lassa epidemiology.
METHODS METHODS
A cross-sectional study was conducted in ten communities located in the Abuja Municipal Area Council (AMAC), Abuja, and Ikorodu Local Government Area (LGA), Lagos, from February 2nd to July 5th, 2022. Serum samples collected from participants were analyzed for IgG and IgM antibodies using a ReLASV
RESULTS RESULTS
A total of 628 participants with serum samples were included in the study. Most participants were female (434, 69%), married (459, 73%), and had a median age of 38 years (interquartile range 28-50). The overall seroprevalence was 27% (171/628), with a prevalence of 33% (126/376) in Abuja and 18% (45/252) in Lagos. Based on site-specific grouped LASSO selection, enrollment in the dry season (vs. wet; aPR, 95% CI: 1.73, 1.33-2.24), reported inconsistent washing of fruits and vegetables (aPR, 95% CI: 1.45, 1.10-1.92), and a positive malaria rapid test (aPR, 95% CI: 1.48, 1.09-2.00) were independently associated with LASV seropositivity in Abuja, whereas, only a self-reported history of rhinorrhea (PR, 95% CI: 2.21, 1.31-3.72) was independently associated with Lassa seropositivity in Lagos.
CONCLUSIONS CONCLUSIONS
The LASV seroprevalence was comparable to that in other areas in Nigeria. Our findings corroborate those from other studies on the importance of limiting human exposure to rodents and focusing on behavioral factors such as poor hygiene practices to reduce exposure to LASV.

Identifiants

pubmed: 39375602
doi: 10.1186/s12879-024-09954-1
pii: 10.1186/s12879-024-09954-1
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118

Subventions

Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237
Organisme : Military Infectious Diseases Research Program, United States Army Medical Research and Development Command,
ID : MI220237

Investigateurs

Adefunke Oladipo-Opashina (A)
Alexus Reynolds (A)
Austin Anikwe (A)
Bahar Dastgheib (B)
Blessing I Wilson (BI)
Bryce Boron (B)
Bwalya Chama (B)
Daniel Choi (D)
Edward Bloom (E)
Ekenedirichukwu Okoli (E)
Gereme Bandong (G)
Helen Nwandu (H)
Igiri Faith (I)
Jenny Lay (J)
Jumoke T Nwalozie (JT)
Lawrence C Umeji (LC)
Mekdi Taddese (M)
Mihret Amare (M)
Michelle Imbach (M)
Nkiru Nnadi (N)
Oyerinde Olunsanya (O)
Sunday Odeyemi (S)
Susan T Mason (ST)
Zubairu Elayo (Z)

Informations de copyright

© 2024. The Author(s).

Références

Pfau CJ. Arenaviruses. In: Baron S, editors. Medical Microbiology. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter: 57.  https://www.ncbi.nlm.nih.gov/books/NBK8193/ .
Auperin DD, Romanowski V, Galinski M, Bishop DH. Sequencing studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral S RNA. J Virol. 1984;52(3):897–904.
pubmed: 6492264 pmcid: 254611 doi: 10.1128/jvi.52.3.897-904.1984
Frame JD, Baldwin JM Jr., Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970;19(4):670–6.
pubmed: 4246571 doi: 10.4269/ajtmh.1970.19.670
Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in west African sub-region: an overview. J Vector Borne Dis. 2007;44(1):1–11.
pubmed: 17378212
Asogun DA, Adomeh DI, Ehimuan J, Odia I, Hass M, Gabriel M, Olschlager S, Becker-Ziaja B, Folarin O, Phelan E, et al. Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis. 2012;6(9):e1839.
pubmed: 23029594 pmcid: 3459880 doi: 10.1371/journal.pntd.0001839
Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, Folarin OA, Goba A, Odia I, Ehiane PE, et al. Clinical sequencing uncovers origins and Evolution of Lassa Virus. Cell. 2015;162(4):738–50.
pubmed: 26276630 pmcid: 4537774 doi: 10.1016/j.cell.2015.07.020
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.
pubmed: 23563266 pmcid: 3651993 doi: 10.1038/nature12060
Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ. 2003;327(7426):1271–5.
pubmed: 14644972 pmcid: 286250 doi: 10.1136/bmj.327.7426.1271
Roberts L. A spiking fever. Science. 2024;383(6685):810–6.
pubmed: 38386723 doi: 10.1126/science.ado7079
Balogun OO, Akande OW, Hamer DH. Lassa Fever: an evolving emergency in West Africa. Am J Trop Med Hyg. 2020;104(2):466–73.
pubmed: 33236712 pmcid: 7866331 doi: 10.4269/ajtmh.20-0487
Lassa Fever. [ https://www.who.int/teams/blueprint/lassa-fever ]
Abdulkarim MA, Babale SM, Umeokonkwo CD, Bamgboye EA, Bashorun AT, Usman AA, Balogun MS. Epidemiology of Lassa fever and Factors Associated with deaths, Bauchi State, Nigeria, 2015–2018. Emerg Infect Dis. 2020;26(4):799–801.
pubmed: 32186504 pmcid: 7101116 doi: 10.3201/eid2604.190678
Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science. 1974;185(4147):263–5.
pubmed: 4833828 doi: 10.1126/science.185.4147.263
Lassa Fever, Transmission. [ https://www.cdc.gov/vhf/lassa/transmission/index.html ]
Lassa fever, Factsheet. [ https://www.afro.who.int/health-topics/lassa-fever#:~:text=Lassa%20virus%20infections%20can%20only,antigen%20detection%20tests ].
Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, Fair J, Guttieri MC, Ferro P, Imes T, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008;78(1):103–15.
pubmed: 18241935 doi: 10.1016/j.antiviral.2007.11.003
McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155(3):437–44.
pubmed: 3805771 doi: 10.1093/infdis/155.3.437
Kayem ND, Benson C, Aye CYL, Barker S, Tome M, Kennedy S, Ariana P, Horby P. Lassa fever in pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2020;114(5):385–96.
pubmed: 32125412 pmcid: 7197258 doi: 10.1093/trstmh/traa011
Isaac AB, Karolina W, Temitope AA, Anuska R, Joanne E, Deborah A, Bianca OC, Filip T, Zofia P, Oluwasegun OI, et al. Prospects of Lassa Fever candidate vaccines. Afr J Infect Dis. 2022;16(2 Suppl):46–58.
pubmed: 36124324 pmcid: 9480887
Demby AH, Chamberlain J, Brown DW, Clegg CS. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol. 1994;32(12):2898–903.
pubmed: 7883875 pmcid: 264198 doi: 10.1128/jcm.32.12.2898-2903.1994
Jahrling PB, Niklasson BS, McCormick JB. Early diagnosis of human lassa fever by ELISA detection of antigen and antibody. Lancet. 1985;1(8423):250–2.
pubmed: 2857321 doi: 10.1016/S0140-6736(85)91029-3
Branco LM, Grove JN, Boisen ML, Shaffer JG, Goba A, Fullah M, Momoh M, Grant DS, Garry RF. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J. 2011;8:478.
pubmed: 22023795 pmcid: 3223505 doi: 10.1186/1743-422X-8-478
Ter Meulen J, Koulemou K, Wittekindt T, Windisch K, Strigl S, Conde S, Schmitz H. Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J Clin Microbiol. 1998;36(11):3143–8.
pubmed: 9774554 pmcid: 105290 doi: 10.1128/JCM.36.11.3143-3148.1998
Grace JA, Egoh IJ, Udensi N. Epidemiological trends of Lassa fever in Nigeria from 2015–2021: a review. Ther Adv Infect Dis. 2021;8:20499361211058252.
pubmed: 34868582 pmcid: 8637796
Dalhat MM, Olayinka A, Meremikwu MM, Dan-Nwafor C, Iniobong A, Ntoimo LF, Onoh I, Mba S, Ohonsi C, Arinze C, et al. Epidemiological trends of Lassa fever in Nigeria, 2018–2021. PLoS ONE. 2022;17(12):e0279467.
pubmed: 36584167 pmcid: 9803109 doi: 10.1371/journal.pone.0279467
Tomori O, Fabiyi A, Sorungbe A, Smith A, McCormick JB. Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg. 1988;38(2):407–10.
pubmed: 3128130 doi: 10.4269/ajtmh.1988.38.407
Bassey O, Bond K, Adedeji A, Oke O, Abubakar A, Yakubu K, Jelpe T, Akintunde E, Ikani P, Ogundiran A, et al. Evaluation of nine HIV rapid test kits to develop a national HIV testing algorithm in Nigeria. Afr J Lab Med. 2015;4(1):1–17.
pubmed: 38440307 pmcid: 10911653 doi: 10.4102/ajlm.v4i1.224
ReLASV
Heinrich ML, Boisen ML, Nelson DKS, Bush DJ, Cross RW, Koval AP, Hoffmann AR, Beddingfield BJ, Hastie KM, Rowland MM, et al. Antibodies from Sierra Leonean and Nigerian lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Sci Rep. 2020;10(1):16030.
pubmed: 32994446 pmcid: 7525497 doi: 10.1038/s41598-020-72539-w
Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, Brown SM, Davis WG, Klena JD, Rollin PE, et al. New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis. 2018;24(3):599–602.
pubmed: 29460758 pmcid: 5823357 doi: 10.3201/eid2403.171905
News Release 12-Sep-2017. Joint West Africa Research Group begins infectious disease surveillance study in Nigeria. [ https://www.eurekalert.org/news-releases/657644 .]
McCauley M, Parker Z, Iroezindu M, Tiamiyu AB, Akinwale E, Paudel M, Milazzo M, Liu H, Chambers J, Bartolanzo D, Li Q, Harrison NE, Parwon Z, Nyarko E, Happi C, Lombardi K, Eller LA, Nosamiefan I, Asiedu W, Broach E, Mebrathu T, Hakre S, Headley J, Prins P, Adams P, Ake J, Amare M, Koehler J, Ricks K, Schoepp R, Ampofo W, Sahnoon H, Fallah M, Bolay F. Letizia A, Sanders T, Fox A, Diclaro J, Vasan S, Michael N, Modjarrad K, Collins N. Seroprevalence of vector-borne and hemorrhagic fever viruses among a cross-section of adult ambulatory and hospitalized patients with severe illness in Nigeria, Ghana, and Liberia, 2017–2022. Kissimmee: Military Health System Research Symposium (MHSRS); 2023.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.
doi: 10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.
doi: 10.1016/j.jbi.2019.103208
Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio. Methods Inf Med. 2004;43(5):505–9.
pubmed: 15702210 doi: 10.1055/s-0038-1633907
Chen Y, Yang Y. The one Standard Error Rule for Model Selection: does it work? Stats vol. 2021;4:868–92.
doi: 10.3390/stats4040051
Miller RE, Breheny P. Marginal false discovery rate control for likelihood-based penalized regression models. Biom J. 2019;61(4):889–901.
pubmed: 30742712 doi: 10.1002/bimj.201800138
Kuhn M, Kjell J. Applied Predictive modeling. New York: Springer. 2013;26:13.
Frndak S, Yu G, Oulhote Y, Queirolo EI, Barg G, Vahter M, Manay N, Peregalli F, Olson JR, Ahmed Z, et al. Reducing the complexity of high-dimensional environmental data: an analytical framework using LASSO with considerations of confounding for statistical inference. Int J Hyg Environ Health. 2023;249:114116.
pubmed: 36805184 pmcid: 10977870 doi: 10.1016/j.ijheh.2023.114116
Agbonlahor DE, Akpede GO, Happi CT, Tomori O. 52 years of Lassa Fever outbreaks in Nigeria, 1969–2020: an epidemiologic analysis of the temporal and spatial trends. Am J Trop Med Hyg. 2021;105(4):974–85.
pubmed: 34460421 pmcid: 8592130 doi: 10.4269/ajtmh.20-1160
Kenmoe S, Tchatchouang S, Ebogo-Belobo JT, Ka’e AC, Mahamat G, Guiamdjo Simo RE, Bowo-Ngandji A, Demeni Emoh CP, Che E, Tchami Ngongang D, et al. Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-saharan Africa. PLoS Negl Trop Dis. 2020;14(8):e0008589.
pubmed: 32845889 pmcid: 7478710 doi: 10.1371/journal.pntd.0008589
Fichet-Calvet E, Lecompte E, Koivogui L, Soropogui B, Dore A, Kourouma F, Sylla O, Daffis S, Koulemou K, Ter Meulen J. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. Vector Borne Zoonotic Dis. 2007;7(2):119–28.
pubmed: 17627428 doi: 10.1089/vbz.2006.0520
Gibb R, Moses LM, Redding DW, Jones KE. Understanding the cryptic nature of Lassa fever in West Africa. Pathog Glob Health. 2017;111(6):276–88.
pubmed: 28875769 pmcid: 5694855 doi: 10.1080/20477724.2017.1369643
Redding DW, Gibb R, Dan-Nwafor CC, Ilori EA, Yashe RU, Oladele SH, Amedu MO, Iniobong A, Attfield LA, Donnelly CA, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. Nat Commun. 2021;12(1):5759.
pubmed: 34599162 pmcid: 8486829 doi: 10.1038/s41467-021-25910-y
Leirs H, Verhagen R, Verheyen W. The basis of reproductive seasonally in Mastomys rats (Rodentia: Muridae) in Tanzania. J Trop Ecol. 1994;10(1):55–66.
doi: 10.1017/S0266467400007719
Ochei O, Abjejegah C, Okoh EC, Abah SO. Housing factors and transmission of Lassa fever in a rural area of south Nigeria. Gen Health Med Sci. 2014;1:15–20.
Ter Meulen J, Lukashevich I, Sidibe K, Inapogui A, Marx M, Dorlemann A, Yansane ML, Koulemou K, Chang-Claude J, Schmitz H. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg. 1996;55(6):661–6.
pubmed: 9025695 doi: 10.4269/ajtmh.1996.55.661
Kerneis S, Koivogui L, Magassouba N, Koulemou K, Lewis R, Aplogan A, Grais RF, Guerin PJ, Fichet-Calvet E. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study. PLoS Negl Trop Dis. 2009;3(11):e548.
pubmed: 19924222 pmcid: 2771900 doi: 10.1371/journal.pntd.0000548
Fichet-Calvet E. Chapter 5 - Lassa Fever: A rodent-human interaction. In: Johnson N, editor.  The Role of Animals in Emerging Viral Diseases. Boston: Academic Press: 2014, p 89–123.  https://doi.org/10.1016/B978-0-12-405191-1.00005-3 .
Clark J, Yakob L, Douno M, Lamine J, Magassouba N, Fichet-Calvet E, Mari-Saez A. Domestic risk factors for increased rodent abundance in a Lassa fever endemic region of rural Upper Guinea. Sci Rep. 2021;11(1):20698.
pubmed: 34667210 pmcid: 8526584 doi: 10.1038/s41598-021-00113-z
Olayinka AT, Elimian K, Ipadeola O, Dan-Nwafor C, Gibson J, Ochu C, Furuse Y, Iniobong A, Akano A, Enenche L, et al. Analysis of sociodemographic and clinical factors associated with Lassa fever disease and mortality in Nigeria. PLOS Glob Public Health. 2022;2(8):e0000191.
pubmed: 36962735 pmcid: 10022364 doi: 10.1371/journal.pgph.0000191
McCormick JB, King IJ, Webb PA, Johnson KM, O’Sullivan R, Smith ES, Trippel S, Tong TC. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987;155(3):445–55.
pubmed: 3805772 doi: 10.1093/infdis/155.3.445
Olayinka AT, Nwafor CD, Akano A, Jan K, Ebhodaghe B, Elimian K, Ochu C, Okwor T, Ipadeola O, Ukponu W, et al. Research as a pillar of Lassa fever emergency response: lessons from Nigeria. Pan Afr Med J. 2020;37:179.
pubmed: 33447334 pmcid: 7778227 doi: 10.11604/pamj.2020.37.179.26425
Segun OE, Shohaimi S, Nallapan M, Lamidi-Sarumoh AA, Salari N. Statistical modelling of the effects of Weather factors on Malaria occurrence in Abuja, Nigeria. Int J Environ Res Public Health. 2020;17(10). https://doi.org/10.3390/ijerph17103474 .
Okokhere P, Colubri A, Azubike C, Iruolagbe C, Osazuwa O, Tabrizi S, Chin E, Asad S, Ediale E, Rafiu M, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis. 2018;18(6):684–95.
pubmed: 29523497 pmcid: 5984133 doi: 10.1016/S1473-3099(18)30121-X
De Silva PM, Marshall JM. Factors contributing to urban malaria transmission in sub-saharan Africa: a systematic review. J Trop Med. 2012;2012:819563.
pubmed: 23125863 pmcid: 3483782 doi: 10.1155/2012/819563
Chiziba C, Mercer LD, Diallo O, Bertozzi-Villa A, Weiss DJ, Gerardin J, Ozodiegwu ID. Socioeconomic, demographic, and Environmental Factors May Inform Malaria Intervention Prioritization in Urban Nigeria. Int J Environ Res Public Health. 2024;21(1). https://doi.org/10.3390/ijerph21010078 .

Auteurs

Abdulwasiu B Tiamiyu (AB)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.
Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.

Olutunde A Adegbite (OA)

68 Nigerian Army Reference Hospital, Lagos, Nigeria.
Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Olivia Freides (O)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Seth Frndak (S)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Samirah Sani Mohammed (SS)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Erica Broach (E)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Kara Lombardi (K)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Victor Anyebe (V)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Roseline Akiga (R)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.
Defence Reference Laboratory, Abuja, Nigeria.

Ndubuisi C Okeke (NC)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Jegede E Feyisayo (JE)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.
Defence Reference Laboratory, Abuja, Nigeria.

Oscar Ugwuezumba (O)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Cassandra Akinde (C)

68 Nigerian Army Reference Hospital, Lagos, Nigeria.
Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Anthonia Osuji (A)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Norah Agu (N)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Tope Analogbei (T)

Ministry of Defence Health Implementation Programme, Abuja, Nigeria.

Chinelo Ekweremadu (C)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Danielle Bartolanzo (D)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Petra Prins (P)

Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.

Ying Fan (Y)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Doris Emekaili (D)

68 Nigerian Army Reference Hospital, Lagos, Nigeria.
Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Felicia Abah (F)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Vincent Chiwetelu (V)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Paul Dike (P)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Esther Isaiah (E)

68 Nigerian Army Reference Hospital, Lagos, Nigeria.
Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Miriam Ayogu (M)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Eunice Ogunkelu (E)

Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Uzoamaka C Agbaim (UC)

68 Nigerian Army Reference Hospital, Lagos, Nigeria.

Adelekun Bukunmi (A)

Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Yakubu Adamu (Y)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Tsedal Mebrahtu (T)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Anastasia Zuppe (A)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Matthew Johnston (M)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Kayvon Modjarrad (K)

Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.

Helina Meri (H)

United States Army Medical Research Directorate-Africa, Abuja, Nigeria.

Zahra Parker (Z)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Edward Akinwale (E)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.

Melanie D McCauley (MD)

Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Glenna Schluck (G)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

David B King (DB)

Health Initiatives For Safety and Stability in Africa, Abuja, Nigeria.

Leigh Anne Eller (LA)

Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America.

Nathan Okeji (N)

Ministry of Defence Health Implementation Programme, Abuja, Nigeria.

Ojor R Ayemoba (OR)

Ministry of Defence Health Implementation Programme, Abuja, Nigeria.

Natalie D Collins (ND)

Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.

Michael O Iroezindu (MO)

HJF Medical Research International Ltd/Gte, Abuja, Nigeria.
Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.

Shilpa Hakre (S)

Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America. shakre@eidresearch.org.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, United States of America. shakre@eidresearch.org.
Viral Diseases Program, 6720-A Rockledge Drive, Suite 400, Bethesda, MD, 20817, USA. shakre@eidresearch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH